Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01580501 · ClinicalTrials.gov registry record · Phase 1
PDE Inhibitors in DMD Study (Acute Dosing Study)
A Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01580501 is a Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT01580501, a Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
PDE5A inhibition, which boosts NO-cGMP signaling, will relieve functional muscle ischemia and restore normal blood flow regulation (i.e., functional sympatholysis) during exercise in boys with DMD. The investigators specific aim is to perform an efficient dose-titration study to inform the design of a randomized multicenter trial of PDE5A inhibition for clinical skeletal muscle and cardiac endpoints.
Interventions
- DRUG Tadalafil and Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01580501
The ClinicalTrials.gov registry entry for NCT01580501 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tadalafil and Sildenafil is the first listed.
NCT01580501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01580501 about?
NCT01580501 is a clinical study titled "PDE Inhibitors in DMD Study (Acute Dosing Study)". PDE5A inhibition, which boosts NO-cGMP signaling, will relieve functional muscle ischemia and restore normal blood flow regulation (i.e., functional sympatholysis) during exercise in boys with DMD. The investigators specific aim is to perform an efficient dose-titration study to inform the design of...
What is the current status of trial NCT01580501?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-03.
What interventions are being tested in trial NCT01580501?
The interventions under investigation include: Tadalafil and Sildenafil (DRUG).
Who is sponsoring clinical trial NCT01580501?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.